Breath: The New Science of a Lost Art

Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines

Retrieved on: 
Thursday, February 16, 2023

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Based in Pittsburgh, Ocean Genomics creates software that provides modeling and an understanding of changes and variants in mRNA to enable a more accurate prediction of a patient’s biological response to a drug.
  • In collaboration with Ocean Genomics, biopharma companies use the technology in in-silico drug discovery to develop treatments based on an individual's personal biology.
  • The global personalized medicine market size is expected to reach more than $796 billion by 2028.
  • “As biopharma companies move to increasingly precise and effective therapies, they seek the talent, technology and insights to enable more personalized, data-driven drug discovery,” said Carl Kingsford, Ph.D., co-founder and CEO of Ocean Genomics.

Vyaire Medical Debuts New Corporate Brand Affirming Commitment to Innovation that Enhances Quality of Breathing

Retrieved on: 
Wednesday, April 14, 2021

Our new brand identity is meant to acknowledge that notion and reflect the passion and urgency Vyaire brings to market through solutions that enhance and support breathing through every stage of life.

Key Points: 
  • Our new brand identity is meant to acknowledge that notion and reflect the passion and urgency Vyaire brings to market through solutions that enhance and support breathing through every stage of life.
  • "\nThe breadth and scale of the Vyaire portfolio is unmatched anywhere in the world.
  • At Vyaire, we pledge to advance innovation and evolve what\'s possible to ensure every breath is taken to its fullest.
  • Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/vyaire-medical-debuts-new-corpor...\n'

Signifier Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence

Retrieved on: 
Monday, March 1, 2021

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA , the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN Award in the Medical category.

Key Points: 
  • Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA , the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN Award in the Medical category.
  • This award further demonstrates the value of eXciteOSA as a proven, transformative treatment for patients with a design optimized for ease of use and high functionality.
  • The GOOD DESIGN award is presented by The Chicago Athenaeum Museum of Architecture and Design and The European Centre for Architecture Art Design and Urban Studies .
  • Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep disordered breathing conditions and snoring.